Screening Tests for Thyroid Dysfunction
High or low thyroid stimulating hormone (TSH) level is indicative of a dysfunctional thyroid.
Source: medindia.net
Thyroid Association Guidelines News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Thyroid Association Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Thyroid Association Guidelines Today - Breaking & Trending Today
Thyroid cancer
The past 5–10 years have brought in a new era in the care of patients with thyroid cancer, with the introduction of transformative diagnostic and management options. Several international ultrasound-based thyroid nodule risk stratification systems have been developed with the goal of reducing unnecessary biopsies. Less invasive alternatives to surgery for low-risk thyroid cancer, such as active surveillance and minimally invasive interventions, are being explored. New systemic therapies are now available for patients with advanced thyroid cancer.
Source: thelancet.com
Ipsen: ASCO 2022: New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
COSMIC-021 Phase Ib study is evaluating Cabometyx (cabozantinib) in combination with atezolizumab in advanced solid tumors, including non-small cell lung cancer New analyses from pivotal Phase
Source: finanznachrichten.de
Ipsen: European Commission Approves Cabometyx as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 This milestone
Source: finanznachrichten.de
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Rad
Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx® (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1This milestone marks the first treatment option to be specifically approved as a second-line therapy in this indicationDisclaimer: Intende...
Source: pharmiweb.com